ArticleScientific reports2025
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of somatostatin analogues on glucose metabolism: A systematic review and network Meta-Analysis of randomized controlled trials.Endocrine · 2026Pooled it
- Pharmacovigilance analysis of glycoprotein IIb/IIIa inhibitors: A FAERS-based signal detection study.Medicine · 2026Article
- Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database.Frontiers in medicine · 2026Article
- Safety evaluation of cinacalcet: Signal mining and analysis of adverse events based on the FAERS database.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases. This study aims to compare the adverse event profiles of Lanreotide and Octreotide in somatostatin-responsive diseases using FAERS data. FAERS data from Q1 2004 to Q2 2024 were reviewed for AE reports related to Lanreotide and Octreotide. Reports were categorized using MedDRA system organ classes (SOCs). Disproportionality analysis was conducted using Reporting Odds Ratios (ROR), Proportional Reporting Ratios (PRR), and Information Components (IC) to identify significant AEs. The top 20 AEs for each drug were analyzed, and chi-square tests assessed differences in AE frequencies between the drugs. Detailed comparisons were made across gastrointestinal, cardiovascular, and neoplastic AEs. Lanreotide was more associated with gastrointestinal AEs, such as diarrhea (1457 reports) and cholelithiasis (198 reports), with a notable signal for cholelithiasis (ROR 12.03, 95% CI 10.46-13.85). Octreotide had higher reports of cardiovascular AEs, including systolic (1483 reports) and diastolic (541 reports) blood pressure increases. Additionally, Octreotide was linked to neoplasm progression (1735 reports) and more frequent malignant neoplasms. Injection site reactions, including pain and nodules, were more common with Lanreotide (ROR 19.09, 95% CI 17.2-21.19). Lanreotide and Octreotide exhibit distinct adverse event profiles, with gastrointestinal signals more frequently observed for Lanreotide, and cardiovascular/neoplastic signals more apparent for Octreotide. These patterns should be interpreted with caution due to limitations of the FAERS data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.